Trump administration unfreezes $600M for Gavi global vaccine effort
The Trump administration has agreed to release $600 million in US funding for Gavi, the global vaccine alliance, after the money had been withheld. The decision matters because Gavi helps fund immunisation programmes in lower-income countries, and the delayed funding had raised concerns about continuity of vaccination efforts.
Congress appropriated $300 million for Gavi in each of the 2025 and 2026 financial years. The administration had linked the funding dispute to concerns over thimerosal, a vaccine preservative, while Gavi said it would use the money to support malaria and other immunisation programmes.
In short
- US releases $600 million for Gavi vaccine programmes
- Funding covered 2025 and 2026 appropriations
- Gavi plans malaria and wider immunisation support
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Releasing the $600 million honours funds Congress appropriated and helps Gavi maintain vaccination programmes in lower-income countries, including malaria prevention. Supporters can argue that predictable funding protects continuity of care and reduces the risk that delays will leave children and other vulnerable groups without immunisation.
The case against
The administration can argue that releasing public funds should be contingent on addressing concerns about how Gavi evaluates vaccine safety, including its position on thimerosal. From this perspective, scrutiny and conditions are a legitimate way to ensure accountability and public confidence before committing substantial taxpayer funding.
Explained simply
Gavi is a global vaccine alliance that helps fund immunisation programmes in lower-income countries. The organisation works to increase access to vaccines in developing nations where health systems may lack the resources to provide widespread vaccination coverage.
Congress appropriates funds for Gavi as part of US international aid. The United States provided $300 million in each of the 2025 and 2026 financial years to support the alliance's work.
A funding dispute emerged between the administration and Gavi over vaccine standards, specifically concerning the use of thimerosal, a preservative ingredient in some vaccines. The disagreement raised concerns about potential disruptions to vaccination programmes in developing countries that depend on American funding.
Government Health Medicine Politics